CY1107470T1 - Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι - Google Patents

Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι

Info

Publication number
CY1107470T1
CY1107470T1 CY20061100939T CY061100939T CY1107470T1 CY 1107470 T1 CY1107470 T1 CY 1107470T1 CY 20061100939 T CY20061100939 T CY 20061100939T CY 061100939 T CY061100939 T CY 061100939T CY 1107470 T1 CY1107470 T1 CY 1107470T1
Authority
CY
Cyprus
Prior art keywords
proteins
leptin
compositions
glycosylated
methods
Prior art date
Application number
CY20061100939T
Other languages
English (en)
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1107470T1 publication Critical patent/CY1107470T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με συνθέσεις γλυκοσυλιωμένης λεπτίνης και με σχετικές μεθόδους. Περιλαμβάνονται γλυκοσυλιωμένες πρωτεΐνες λεπτίνης που έχουν ακτίνα Stokes που εκχωρεί βελτιωμένες ιδιότητες, όπως επίσης και γλυκοσυλιωμένες πρωτεΐνες λεπτίνης που έχουν επιλεγμένες θέσεις για γλυκοσυλίωση, νουκλεϊκά οξέα που κωδικοποιούν αυτές τις πρωτεΐνες, σχετικά κύτταρα-ξενιστές, φορείς, διαδικασίες παραγωγής, και μέθοδοι χρήσεις αυτών των συνθέσεων. Παρέχονται επίσης πρωτότυπες μέθοδοι παραγωγής γλυκοσυλιωμένων πρωτεϊνών. Η γλυκοσυλιωμένη πρωτεΐνη λεπτίνης μπορεί να χρησιμοποιηθεί στην παρασκευή φαρμακευτικής σύνθεσης που μπορεί να χρησιμοποιηθεί στην θεραπευτική αγωγή ανθρώπου για πάθηση που επιλέγεται από παχυσαρκία, διαβήτη και υψηλό περιεχόμενο λιπιδίων αίματος.
CY20061100939T 1999-02-12 2006-07-07 Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι CY1107470T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12
EP00911784A EP1151102B1 (en) 1999-02-12 2000-02-11 Glycosylated leptin compositions and related methods

Publications (1)

Publication Number Publication Date
CY1107470T1 true CY1107470T1 (el) 2012-12-19

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100939T CY1107470T1 (el) 1999-02-12 2006-07-07 Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι

Country Status (11)

Country Link
EP (1) EP1151102B1 (el)
JP (1) JP4841037B2 (el)
AT (1) ATE323766T1 (el)
AU (1) AU781460B2 (el)
CA (1) CA2359840C (el)
CY (1) CY1107470T1 (el)
DE (1) DE60027409T2 (el)
DK (1) DK1151102T3 (el)
ES (1) ES2257287T3 (el)
PT (1) PT1151102E (el)
WO (1) WO2000047741A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2459015A1 (en) * 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
DE60237100D1 (de) * 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
ATE448312T1 (de) 2003-09-26 2009-11-15 Merck Serono Sa Leitsequenzen zur verwendung bei der produktion von proteinen
EP2586456B1 (en) 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
BR112013007388B1 (pt) 2010-09-28 2022-01-04 Amylin Pharmaceuticals, Llc Polipeptídeo tendo domínio de ligação de albumina e leptina, seu uso no tratamento de doenças, bem como composição farmacêutica que o compreende
KR102434075B1 (ko) 2012-05-17 2022-08-19 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
CA2886393C (en) 2012-09-27 2019-02-26 The Children's Medical Center Corporation Pentacyclic triterpenes for the treatment of obesity
US20160375039A1 (en) 2013-11-26 2016-12-29 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
PL3509624T3 (pl) 2016-09-12 2024-03-25 Amryt Pharmaceuticals Inc. Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
ZA946122B (en) * 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
AU2246097A (en) * 1996-01-25 1997-08-20 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
EP0827750A3 (en) * 1996-08-23 2002-11-20 Eli Lilly And Company Obesity protein formulations
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs
DE69921486T2 (de) * 1998-08-10 2006-02-02 Amgen Inc., Thousand Oaks Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
DE60027409D1 (de) 2006-05-24
WO2000047741A1 (en) 2000-08-17
EP1151102A1 (en) 2001-11-07
DE60027409T2 (de) 2007-04-12
JP2002536018A (ja) 2002-10-29
CA2359840C (en) 2012-10-23
JP4841037B2 (ja) 2011-12-21
ATE323766T1 (de) 2006-05-15
DK1151102T3 (da) 2006-05-29
CA2359840A1 (en) 2000-08-17
ES2257287T3 (es) 2006-08-01
PT1151102E (pt) 2006-07-31
AU3362300A (en) 2000-08-29
AU781460B2 (en) 2005-05-26
EP1151102B1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
CY1107470T1 (el) Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι
AU2001254624A1 (en) Human coagulation factor vii variants
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
WO2003059934A3 (en) Albumin fusion proteins
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
ATE277081T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
AU2003215524A1 (en) Pharmaceutical compositions comprising mannose binding lectin
EP1832599A3 (en) Albumin fusion proteins
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EP2325205A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NZ223506A (en) Tissue factor protein, dna encoding it, vectors, host cells, production of the protein and pharmaceutical compositions
EP0797999A3 (en) Formulations of obesity protein
WO1995025171A3 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
ATE367826T1 (de) Impfstoffe, die hybride polypeptide mit mindestens zwei verschiedene allergenen enthalten
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida
ATE331032T1 (de) Glutamine: fructose-6-phosphat amidotransferase (gfat), ihre herstellung und verwendung
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
FI964186A (fi) Ei-liittävät gp350/220-variantit
EP1801123A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
BR0211991A (pt) HormÈnio do crescimento humano modificado